Clinical Study
A Nonimmunosuppressant Approach on Asia Psoriasis Subjects: 5-Year Followup and 11-Year Data Analysis
Table 2
Baseline characteristics and follow-up data of the 1215 psoriasis patients with herose treatment.
| | Baseline | Month 1 | Month 3 | Month 6 | Month 12 | Month 18 | Month 60 | | | | | | | | |
| | Age (yr) at herose initiation, mean (range) | 42.4 (18–71) | 41.7 (19–70) | 41.7 (22–68) | 42 (22–68) | 41.7 (22–68) | 41.9 (22–66) | 41.5 (22–62) | | Psoriasis duration (yr) before herose treatment, mean (range) | 9.7 (1–39) | 9.5 (1–39) | 9.6 (1–39) | 9.4 (1–39) | 9.5 (1–39) | 9.4 (1–25) | 8.6 (1–25) | | PASI score, mean (range) | 28.9 (3.6–68) | 39.7 (6.2–70) | 45.2 (9.4–72) | 38.4 (0–70) | 29 (0–63.1) | 32.7 (0–58.3) | 1.4 (0–16.4) | | Cumulated previous immunosuppressants treatment (mo), (%) | | | | | | | | | Null | 16 (1.3%) | 16 (1.8%) | 16 (3%) | 14 (3.1%) | 14 (3.9%) | 14 (6.4%) | 14 (7.4%) | | <6 months | 588 (48.4%) | 430 (49.5%) | 268 (50.8%) | 227 (50.6%) | 164 (46.2%) | 101 (46.3%) | 95 (50%) | | 6–12 months | 332 (27.3%) | 231 (26.6%) | 135 (25.6%) | 116 (25.8%) | 95 (26.8%) | 54 (24.8%) | 68 (35.8%) | | 12–24 months | 170 (14%) | 115 (13.2%) | 79 (15%) | 73 (16.3%) | 63 (17.7%) | 38 (17.4%) | 13 (6.8%) | | 24–36 months | 33 (2.7%) | 27 (3.1%) | 6 (1.1%) | 0 | 0 | 0 | 0 | | >36 months | 76 (6.3%) | 49 (5.6%) | 24 (4.5%) | 19 (4.2%) | 19 (5.4%) | 11 (5.1%) | 0 | | Past illness, percentage | | | | | | | | | Hypertension | 141 (11.6%) | | | | | | 14 (7.4%) | | Hyperlipidemia | 103 (8.5%) | | | | | | 9 (4.5%) | | Asthma | 47 (3.9%) | | | | | | 1 (0.6%) | | Arthritis | 123 (10.1%) | | | | | | 16 (8.5%) | | Hepetitis B | 19 (1.6%) | | | | | | 1 (0.6%) | | Diabetes | 28 (2.3%) | | | | | | 0 | | Gastritis | 19 (1.6%) | | | | | | 0 | | Eczema | 18 (1.5%) | | | | | | 1 (0.6%) | | Gout | 18 (1.5%) | | | | | | 0 |
|
|
